Group 1 - The Hang Seng Healthcare Index (HSHCI) has risen by 1.17% as of December 4, 2025, with notable increases in stocks such as InnoCare Pharma (up 4.91%), CanSino Biologics (up 4.65%), and MicroPort Scientific (up 4.51%) [1] - The 11th batch of national centralized procurement results was released on November 7, including 453 products across 55 varieties, with an average price reduction of approximately 75% compared to the highest valid bid [1] - The upcoming ESMO Asia 2025 conference will take place from December 5-7, and the 67th American Society of Hematology (ASH) meeting will be held from December 6-9, which are expected to catalyze data releases in the healthcare sector [1] Group 2 - The top ten weighted stocks in the Hang Seng Healthcare Index (HSHCI) account for 60.48% of the index, including companies like BeiGene, Innovent Biologics, and WuXi Biologics [2] - The Hang Seng Healthcare ETF (159557) closely tracks the HSHCI, providing a market reference for the performance of healthcare securities listed in Hong Kong [2] - Investors without stock accounts can access the Hong Kong healthcare sector investment opportunities through the Hang Seng Healthcare ETF linked fund (018433) [2]

Group 1 - The core viewpoint of the news is that after a four-day decline, the Hong Kong innovative drug sector has rebounded, with leading stocks like Kangfang Biotech and Rongchang Biotech showing significant gains [1][7] - The Hong Kong Stock Connect Innovative Drug ETF (520880) has over 70% of its holdings in leading innovative drug stocks, indicating strong market confidence [1][7] - The innovative drug sector is expected to be a major upward trend in the cross-year market, supported by China's pharmaceutical industry entering a critical phase of "innovation realization + global layout" [3][9] Group 2 - The Hong Kong Stock Connect Innovative Drug ETF (520880) has a total scale of 2.142 billion yuan and an average daily trading volume of 458 million yuan since its listing, making it the largest and most liquid ETF tracking the same index [5][10] - The index tracked by the ETF, the Hang Seng Stock Connect Innovative Drug Select Index, has a high concentration of leading stocks, with the top ten stocks accounting for 72.57% of the total weight, showcasing the strength of the innovative drug sector [3][10] - The ETF is designed to cover pure innovative drug companies without including CXO, ensuring a comprehensive representation of the innovative drug research and development sector [4][9]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 三生制药（「本公司」） 呈交日期: 2025年12月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01530 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 50,000,000,000 | USD | | 0.00001 | USD | | 500,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 50,000,000,000 | USD | | 0.00001 | USD | | 500,000 | 本月底法定 ...

Group 1 - The Hong Kong Innovation Drug ETF (159570) experienced a 1.5% decline, marking its fourth consecutive day of decrease, with a trading volume exceeding 1.3 billion yuan [1] - The ETF has attracted a net inflow of over 6 million yuan during the day and has accumulated over 740 million yuan in the last 10 days, with a total size exceeding 23.6 billion yuan as of December 2 [1] - Major weighted stocks in the ETF, such as 3SBio, Innovent Biologics, and China Biologic Products, saw declines of over 2%, while others like CSPC Pharmaceutical and BeiGene dropped over 1% [2][3] Group 2 - The upcoming ASH conference is expected to reveal key data in the hematology field, which may catalyze the valuation recovery of related pipelines, particularly for companies with differentiated advantages in oncology, autoimmune, and rare disease products [5] - The Chinese innovative drug industry has shown significant growth, with the number of clinical trials increasing from 1,473 in 2020 to 2,539 in 2024, reflecting a compound annual growth rate of over 15% [6][9] - Chinese pharmaceutical companies are becoming increasingly prominent in global research, contributing 27% in oncology and 19% in autoimmune fields, with significant positions in ADC targets such as HER2 and TROP2 [9]

12月3日，港股创新药板块延续调整态势，龙头股集体飘绿，百济神州、信达生物、石药集团齐跌逾 1%，中国生物制药、三生制药跌超2%。 港股通创新药ETF（520880）超7成仓位押注创新药龙头股，持续水下震荡，截至发稿跌逾1%，连续第 4日下跌。不过场内延续宽幅溢价，显示买盘资金相对强势。 | | | 分时 多日 1分 5分 15分 30分 · | | | F9 發前盘后 發加 九越 画坊 丁具 @ (2) | | | 港股通创新药ETF O | | 520880 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 520880[種腔通创新药ETF] 13:19 价 0.553 涨跌 -0.007(-1.25%) 均价 0.556 成交量 | | | | | | | | | 0.570 | | | | | | | | 05 | | -0.007 -1.25% | | 0,567 | | | | | | | 1.2496 | SSE CNY 13:19:54 文明中 | | # ■ Z 版 O+1 | | | ...

投创新药，首选同类最大港股通创新药ETF（520880）及其场外联接基金（025221），标的指数恒生港 股通创新药精选指数具备三大独特优势： 1、纯粹，全面。不含CXO，纯正创新药！全面覆盖创新药研发类公司。 2、龙头占比大。前十大创新药龙头权重超72%，表征创新药硬核力量。 3、风险更可控。对流动性较差的成份股强制降权，有力管控尾部风险。 | | | 港股通创新药ETF (520880) 标的指数 | | | --- | --- | --- | --- | | | | 前十成份股权重高达72.57%，龙头优势显著 | | | 代码 | 简称 | 权重(%) | 总市值(亿港元) | | 6160.HK | 百济神州 | 11.51 | 3,070 | | 1801.HK | 信达生物 | 10.19 | 1,613 | | 1177.HK | 中国生物制药 | 9.47 | 1,323 | | 9926.HK | 康方生物 | 66'8 | 1,132 | | 1093.HK | 石药编团 | 8.39 | 911 | | 1530.HK | 三生制药 | 8.32 | 760 | | 3692.HK | ...

大消费表现不错，截至目前上涨0.65%，其中比亚迪股份大涨3.42%，波司登上涨2.2%，金沙江中国上 涨2.15%，美高梅、复星国际、美的集团、海底捞等超10只个股涨幅在1%上方。 恒生医疗开盘后直线跳水，随后探底回升，截至目前下跌0.3%。其中三生制药大跌3.79%，京东健康下 跌2.36%，百济神州、药明康德、康方生物、石药集团等股均小幅下跌。 内容只是个人观点，仅供参考，不作为投资依据！欢迎关注交流，互相学习、共同探讨！ 恒生指数开盘后直线拉升，随后维持在高位配置，截至目前上涨0.74%。恒生互联网涨幅居前，科技、 大消费紧随其后，恒生医疗和银行逆势回撤。 互联网跌幅高开后探底回升，截至目前上涨0.56%。快手大涨4.1%，阿里巴巴上涨2.78%，网易上涨 1.44%，百度集团、腾讯控股等均小幅上涨；美团、哔哩哔哩、地平线机器人等股逆势回撤。 ...

2025 年 12 月 3 日 星期三 欧盟 11 月通胀率初值为 2.2%,皆高于市场预期的 2.1%及 10 月终值 2.1%。 行业动态： 汽车行业方面，新势力车企周二跑输大盘。蔚来(9866 HK)公布 11 月交付量同比+76.3%，环比-10%，前 11 月完成全年目 标 63%。并且根据国内媒体报道，一辆蔚来 EC6 在上海发生事故，车身断裂。受消息影响，蔚来周二下跌 6.7%至三个月低 位。小鹏汽车(9868 HK)11 月交付量同比+19%，环比-12.6%，是近六个月来首次环比下跌。周二小鹏股价下跌 5.5%。理想 汽车(2015 HK)11 月交付量同比-31.9%，环比+4.5%。股价下跌 0.8%。理想汽车仅完成全年目标销量 56.6%。临近年底， 新能源汽车行业没有出现市场先前预期的"翘尾"行情。 昨日港股医药行业主要企业多数微跌。三生制药(1530 HK)公布按照每股配售股份 29.62 港元的价格向不少于六名承配人 配售合共 1.05 亿股配售股份。配售价较前一个交易日收市价低 6.5%，三生制药昨日股价下跌。配售数量占扩大后已发行 股份总数约 4.14%，我们认为影响有限。公 ...

Summary of Conference Call Records Industry Overview - The pharmaceutical sector underperformed the broader market in November, with pharmaceutical commerce, traditional Chinese medicine, and raw materials performing relatively well [1][5] - The S&P Healthcare Select Sector Index in the US rose by 9.1%, outperforming the S&P 500 Index by 0.1% [5] Key Companies and Recommendations New Additions to Investment Portfolio - **Jin Xin Pharmaceutical**: Added due to its low valuation and stable core business; its LPA project ranks among the top two in China, expected to act as a catalyst [1][6] - **Yi Fang Bio**: Stock price has reached a low point; TIKTOO product is expected to have potential authorization in the next six months, with similar product data from Takeda acting as a catalyst [1][7] - **Te Bao Bio**: Main product Pegasys for hepatitis B has received approval, with new patient numbers increasing; expected to continue high growth next year [1][8][9] Continued Recommendations - **Hengrui Medicine**: Strong R&D pipeline and favorable procurement situation; R&D Day on December 5 is a key event to watch [1][10] - **Medical Device Leaders**: Long-term investment value due to stable competitive landscape and recovery in terminal bidding; many companies reported revenue turning points in Q3 [1][11] Market Trends and Projections - The medical device industry is expected to see a recovery trend in Q4 2025 and 2026, with strong performance in neuro-intervention and neurosurgery sectors [1][12] - The IVD industry may face volume and price pressures in 2025 but is expected to see a turning point in 2026 [1][12][13] Competitive Landscape - China's medical device market is gaining global competitiveness due to advantages in engineering, industrial clusters, supply chains, and clinical resources [1][14] - Despite complexities, Chinese medical devices are competitive globally due to cost-effectiveness; leading companies are increasing overseas revenue [1][14] Individual Company Insights - **Kelong Pharmaceutical**: Faced challenges due to procurement price reductions but is expected to stabilize with rising demand for large-volume infusions [1][16] - **BeiGene**: Anticipated to achieve profitability for the first time, with strong sales performance from its drug Zebrutinib [1][16] Investment Recommendations - Recommended stocks include **United Imaging**, **Lepu Medical**, **Hui Tai**, **Chun Li**, and **New Industry** in the IVD sector [1][15] - **United Imaging**: Expected to continue high growth with new product contributions [1][15] - **Lepu Medical**: Stable core business with growth potential in new sectors [1][15] Future Catalysts - TIK2 inhibitors are expected to show potential in various indications, with significant data releases anticipated [1][18] - Jin Xin Pharmaceutical has completed Phase I clinical trials with satisfactory results, indicating strong potential in the cardiovascular field [1][20][21] Conclusion - The pharmaceutical and medical device sectors are poised for recovery, with specific companies showing strong potential for growth and investment opportunities in the coming years.

Summary of Key Points from Conference Call Records Industry Overview - The pharmaceutical sector experienced a correction in 2025 but rebounded towards the end of the year, with the innovative drug market expected to continue its momentum into 2026, presenting investment opportunities [1][6][10]. - Current industry hotspots include the flu epidemic, policy support, and breakthroughs in innovative fields such as small nucleic acid drugs, GLP-1, and BCL-2 inhibitors [1][7][8]. Core Insights and Arguments - The overall performance of the pharmaceutical sector in November 2025 was weak, with a decline of 3.6%, underperforming the CSI 300 index by approximately 1.16 percentage points [3]. - The application of AI technology in healthcare, including AI medicine and brain-computer interfaces, is gaining attention and is expected to present opportunities in 2026 [4][12]. - The release of the medical insurance negotiation directory and commercial insurance innovation directory will significantly impact the sales of related products once they enter the insurance system [10]. - Investment recommendations for 2026 include focusing on cutting-edge technologies such as dual antibodies, multi-antibodies, ADC, PROTAC, small nucleic acids, and GLP-1, as well as large companies with strong R&D capabilities and biotech firms with best/first-in-class potential [9][11]. Notable Developments - The flu data has reached new highs, driving up the stock prices of related testing drugs and vaccines [7]. - The third-party laboratory sector is expected to see performance bottoming out in Q4 2025, with a recovery starting in Q1 2026, aided by accelerated payment collection from companies like KingMed and Dian Diagnostics [4][19]. - The PROTAC technology is highlighted for its ability to degrade target proteins, addressing issues of drug resistance, with leading companies like Pfizer, BMS, and BeiGene making significant progress [4][16][17]. Investment Opportunities - Companies such as KingMed and Dian Diagnostics are recommended for investment due to their improving cash flow and potential recovery in the IVD industry [19][20]. - Jichuan Pharmaceutical is included in the December portfolio due to its expected performance rebound driven by flu season demand and low inventory levels [21]. - The CRO industry is poised for growth, with expectations of increased outsourcing rates and improved margins due to a decrease in new entrants [22][23]. Future Trends - The medical device sector is showing positive trends, with expectations for improvement in the consumer healthcare segment in 2026 [2][11]. - The potential for significant growth in the insulin business of companies like Lianbang Pharmaceutical is anticipated, with a projected revenue of 20 billion yuan in 2025 [32][35]. - The upcoming KMR data in December is expected to act as a catalyst for the global PROTAC market, with a focus on companies with substantial technology platforms [18]. Conclusion - The pharmaceutical and healthcare sectors are navigating through a period of adjustment, with various innovative technologies and market dynamics presenting both opportunities and challenges. Investors are advised to keep a close watch on regulatory developments, clinical trial outcomes, and emerging technologies that could shape the future landscape of the industry [1][6][10].